FY2025 · ended Dec 31, 2025 · Revenue $33.00M, -35.3% YoY · Filed Feb 25, 2026
Arcus Biosciences, Inc. (RCUS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $33.0 million and a net loss of $353.0 million. Free cash flow was -$484.0 million. As of Sep 30, 2026 it held $694.0 million in cash and investments and $116.0 million in total debt.
Revenue (TTM)
$54.00M
+20.0% vs year-ago TTM
Net income (TTM)
$-453.00M
-32.8% vs year-ago TTM
Operating cash flow (TTM)
$-465.00M
-0.6% vs year-ago TTM
Free cash flow (TTM)
$-466.00M
-0.4% vs year-ago TTM
EPS (TTM)
$-3.64
-7.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
125.35M
+18.4% vs prior year
Net cash
$578.00M
as of Sep 30, 2026
Operating margin
-879.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RCUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1724521
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $33.0M | $51.0M | $37.0M | $38.0M | $383.0M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M |
| Diluted EPS | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.71 |
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B |
| Total liabilities | — | — | — | — | $750.4M |
| Stockholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M |
| Cash and investments | $1.0B | $992.0M | $866.0M | $1.1B | $681.0M |
| Total debt | $198.0M | $159.0M | $121.0M | $126.0M | $113.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 609 Arcus Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.